Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Ticker SymbolIVA
CompanyInventiva SA
CEOObenshain (Andrew)
Websitehttps://inventivapharma.com/
FAQs
What is the current price of Inventiva SA (IVA)?
The current price of Inventiva SA (IVA) is 4.440.
What is the symbol of Inventiva SA?
The ticker symbol of Inventiva SA is IVA.
What is the 52-week high of Inventiva SA?
The 52-week high of Inventiva SA is 7.982.
What is the 52-week low of Inventiva SA?
The 52-week low of Inventiva SA is 2.111.
What is the market capitalization of Inventiva SA?
The market capitalization of Inventiva SA is --.
What is the net income of Inventiva SA?
The net income of Inventiva SA is --.
Is Inventiva SA (IVA) currently rated as Buy, Hold, or Sell?
According to analysts, Inventiva SA (IVA) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Inventiva SA (IVA)?
The Earnings Per Share (EPS TTM) of Inventiva SA (IVA) is --.